• 18491 Citations
1988 …2024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr. Hussain's research is focused on the development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer.

Dr. Hussain is a GU medical oncologist with a focus on prostate and bladder cancer.

Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior to joining the Northwestern University faculty Dr. Hussain has served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology. At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain was a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force. She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE. Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net. She currently serves on the Clinical Practice Guidelines Committee and is an elected member of the ASCO Board of Directors. Dr. Hussain is the author of more than 240 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty publications. She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.

Training Experience

1983Internship, Wayne State University
1986Residency, Wayne State University School of Medicine, Detroit, Michigan
1989Fellowship, Wayne State University School of Medicine, Detroit, Michigan

Education/Academic qualification

MBChB, Baghdad University College of Medicine, Baghdad, Iraq

… → 1980

Fingerprint Dive into the research topics where Maha Hussain is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Androgens Medicine & Life Sciences
Castration Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Hormones Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2014 2024

Organized Financing
Neoplasms
Medicine
Research
Population
Pharmaceutical Preparations
Neoplasms
Medicine
Research
Population

ETCTN Participation

Hussain, M.

National Cancer Institute

8/10/187/31/23

Project: Research project

Neoplasms
Medicine
Research
Population

Research Output 1988 2019

Neoadjuvant Therapy
Urinary Bladder Neoplasms
Muscles
Therapeutics
2 Citations (Scopus)

Inflammatory Bowel Disease and the Risk of Prostate Cancer

Burns, J. A., Weiner, A. B., Catalona, W. J., Li, E. V., Schaeffer, E. M., Hanauer, S. B., Strong, S. A., Burns, J., Hussain, M. & Kundu, S. D., May 1 2019, In : European urology. 75, 5, p. 846-852 7 p.

Research output: Contribution to journalArticle

Inflammatory Bowel Diseases
Prostatic Neoplasms
Prostate-Specific Antigen
Safety Management
Incidence
4 Citations (Scopus)

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Tombal, B., Saad, F., Penson, D., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C. & Attard, G., Apr 1 2019, In : The Lancet Oncology. 20, 4, p. 556-569 14 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Pain
Quality of Life
1 Citation (Scopus)

Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?

Shevach, J., Sydes, M. R. & Hussain, M., Mar 1 2019, In : European Urology Focus. 5, 2, p. 125-133 9 p.

Research output: Contribution to journalReview article

docetaxel
Androgens
Prostatic Neoplasms
Standard of Care
Prednisone

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421

Lara, P. N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N. J., Hussain, M., Twardowski, P. W., Garzotto, M. G., Monk, J. P., Carducci, M., Goldkorn, A., Mack, P. C., Thompson, I., Van Loan, M. & Quinn, D. I., Jan 1 2018, In : Cancer Treatment and Research Communications. 16, p. 18-23 6 p.

Research output: Contribution to journalArticle

bis(2,3,3,3-tetrachloropropyl) ether
Bone Remodeling
Castration
Prostatic Neoplasms
Biomarkers